BookMassimo Filippi, Maria A. Rocca.
Contents:
Intro
Acknowledgements
Introduction
Contents
1: Multiple Sclerosis
1.1 Introduction
1.2 Epidemiology
1.3 Etiopathogenesis
1.3.1 Genetic Susceptibility
1.3.2 Environmental Risk Factors
1.3.3 Pathology
1.3.4 Immunopathophysiology
1.4 Clinical Manifestations
1.4.1 Clinical Features
1.4.2 Clinical Phenotypes
1.5 Diagnostic Procedures
1.5.1 MRI
1.5.2 Cerebrospinal Fluid Examination
1.5.3 Evoked Potentials
1.5.4 Diagnostic Criteria
1.5.5 Differential Diagnosis
1.5.6 Biomarkers and Prognostic Factors 1.6 Treatment Approaches
1.6.1 DMDs for RRMS
1.6.2 DMDs for Progressive MS
1.6.3 Monitoring Treatment Response
1.6.4 Treatments Under Investigation
1.6.5 Management of Relapses
1.6.6 Symptomatic Treatments
References
2: Pediatric Multiple Sclerosis
2.1 Introduction
2.2 Epidemiology
2.3 Etiopathogenesis
2.3.1 Genetic Risk Factors
2.3.2 Environmental Risk Factors
2.3.3 Epigenetics
2.3.4 Pathology
2.3.5 Immune Pathophysiology
2.4 Clinical Manifestations
2.4.1 The First Demyelinating Event
2.4.2 Pediatric MS 2.4.3 Disease Course
2.4.4 Cognitive Impairment
2.4.5 Fatigue, Mood, and Behavioral Disturbances
2.5 Diagnostic Procedures
2.5.1 MRI
2.5.2 Cerebrospinal Fluid Examination
2.5.3 Autoantibodies
2.5.4 Neurophysiological Studies
2.5.5 Diagnostic Criteria
2.5.6 Differential Diagnosis
2.5.7 Advanced MRI Techniques
2.5.8 Neurofilaments
2.6 Treatment Approaches
2.6.1 Acute Management
2.6.2 DMTs
2.6.2.1 First-Line DMTs
2.6.2.2 Second-Line DMTs
2.6.3 Treatment Monitoring
2.6.4 Vitamin-D Supplementation
2.6.5 Symptomatic Treatments 2.6.6 Counseling and Support
References
3: Neuromyelitis Optica Spectrum Disorders
3.1 Introduction
3.2 Epidemiology
3.2.1 Geographic Distribution
3.2.2 Demographic Features
3.3 Etiopathogenesis
3.4 Clinical Manifestations
3.4.1 Core Clinical Characteristics
3.4.2 Other Manifestations
3.4.3 Natural History of NMOSD
3.4.4 Rare Phenotypes
3.4.5 Differential Diagnosis
3.5 Diagnostic Procedures
3.5.1 Antibody Testing
3.5.2 Cerebrospinal Fluid Examination
3.5.3 MRI Features
3.6 Treatment Approaches
3.6.1 Treatment of Relapses 3.6.2 Chronic Treatment (Prevention of Relapses)
3.6.3 Symptomatic Treatments
References
4: Anti-MOG Diseases
4.1 Introduction
4.2 Epidemiology
4.2.1 Demographic Features
4.2.2 Risk Factors
4.3 Etiopathogenesis
4.4 Clinical Manifestations
4.4.1 Typical Clinical Findings
4.4.2 Natural History of Anti-MOG Disease
4.5 Diagnosis
4.5.1 Differential Diagnosis
4.6 Diagnostic Procedures
4.6.1 Antibody Testing
4.6.2 Cerebrospinal Fluid Examination
4.6.3 MRI Features
4.6.4 Visual Evoked Potentials and Optical Coherence Tomography